Summit TherapeuticsSMMT
SMMT
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
172% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 25
97% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 38
23% more funds holding
Funds holding: 164 [Q3] → 202 (+38) [Q4]
0.87% more ownership
Funds ownership: 11.68% [Q3] → 12.55% (+0.87%) [Q4]
11% less capital invested
Capital invested by funds: $1.85B [Q3] → $1.65B (-$199M) [Q4]
32% less call options, than puts
Call options by funds: $36.7M | Put options by funds: $53.9M
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
46%
upside
Avg. target
$36
76%
upside
High target
$44
114%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz 16% 1-year accuracy 7 / 43 met price target | 70%upside $35 | Buy Upgraded | 26 Mar 2025 |
Evercore ISI Group Cory Kasimov 44% 1-year accuracy 7 / 16 met price target | 46%upside $30 | Outperform Initiated | 12 Mar 2025 |
Goldman Sachs Salveen Richter 29% 1-year accuracy 5 / 17 met price target | 104%upside $42 | Buy Initiated | 28 Feb 2025 |
Citizens Capital Markets Reni Benjamin 24% 1-year accuracy 10 / 42 met price target | 55%upside $32 | Market Outperform Reiterated | 25 Feb 2025 |
HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 60 / 182 met price target | 114%upside $44 | Buy Reiterated | 25 Feb 2025 |
Financial journalist opinion
Based on 10 articles about SMMT published over the past 30 days
Negative
The Motley Fool
1 day ago
Why Summit Therapeutics Stock Slipped Today
Summit Therapeutics (SMMT -2.25%) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (^GSPC -1.12%), managing to dip by a relatively modest 2.25% in price.
Positive
Proactive Investors
1 day ago
Summit Therapeutics upgraded ahead of lung cancer trial data readout
Summit Therapeutics PLC (NASDAQ:SMMT) has been upgraded to a ‘Buy' rating by Citi analysts who are optimistic about the company's HARMONi-2 trial of ivonescimab in non-small cell lung cancer. Citi also boosted its price target to $35.
Positive
Benzinga
3 days ago
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Positive
The Motley Fool
4 days ago
Is Summit Therapeutics a Millionaire Maker?
Multiple paths to immense wealth exist. A few lucky people win the lottery.
Neutral
Business Wire
6 days ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Commit.
Positive
The Motley Fool
1 week ago
This Unstoppable Biotech Stock Just Became an Even Better Buy
Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.
Neutral
Business Wire
1 week ago
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, “Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our te.
Neutral
Business Wire
1 week ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 122,650 shares of common stock. Awards were made to 12 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.
Positive
The Motley Fool
1 week ago
Why Summit Therapeutics Stock Was Winning This Week
A very bullish analyst move was the news generally responsible for Summit Therapeutics' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market open, as according to data compiled by S&P Global Market Intelligence Summit's share price had risen by almost 8% week to date at that point.
Positive
The Motley Fool
2 weeks ago
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Summit Therapeutics (SMMT 7.62%) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since the start of 2025, the stock's returns have been flat.
Charts implemented using Lightweight Charts™